Skip to content
Legislation to encourage innovation and protect patent holders should not be distorted into instruments for drug price controls, a high-profile group of former judges, […]
Top legal experts: Laws protecting IP aren’t tools for drug price controls Read More »
Generated by our own internal defenses, sepsis claims 350,000 adult lives each year in the United States and is the most costly condition behind
Battling sepsis and superbugs requires awareness and policy Read More »
Drug price controls in the Inflation Reduction Act (IRA) harm the development of new drugs, according to Sept. 20 testimony in Congress from John
BIO Vice Chair John F. Crowley to Congress: IRA reduces access to innovative drugs Read More »
Horseshoe crabs have been living in the ocean for almost half a billion years, surviving five mass extinctions. However, their use in lab tests
Drug makers promote new toxin testing technology to spare horseshoe crabs Read More »
The Biotechnology Innovation Organization (BIO) filed an amicus brief opposing the Federal Trade Commission (FTC) lawsuit to block Amgen’s acquisition of Horizon, arguing that
BIO to file amicus brief opposing FTC interference in vital biotech merger activity Read More »
The challenge of preventing pharmacy benefit managers (PBMs) from driving up drug prices was front and center on Capitol Hill this week. Bipartisan legislation
Congress puts PBMs in the spotlight during a busy week on Capitol Hill Read More »
With so many life-science advances starting on the farm, the 2023 Farm Bill, which sets U.S. agriculture policy for the next five years, is
Why the 2023 Farm Bill matters to biotech Read More »
Although further research is being conducted to ease potential concerns, the recommended childhood vaccines are safe and provide essential protection, experts told a June
Benefits of childhood vaccination outweigh possible risks, experts tell CDC Read More »
A June 21 House hearing on health care costs put a sharp focus on the need for transparency to prevent pharmacy benefit managers (PBMs)
House hearing puts focus on need for PBM transparency Read More »
Intellectual property (IP) protections need reform but the current Congress may not have the consensus to achieve these changes, a panel of Capitol Hill
Congress may lack consensus needed for IP reform this year, BIO panelists say Read More »
